News
BMY-RT
0.6901
-42.97%
-0.5199
Bristol Myers CFO David Elkins sells USD 1.85 million common shares
Reuters · 2d ago
Harmony Biosciences names Peter Anastasiou COO in executive reshuffle
Reuters · 3d ago
Coya Therapeutics names Mark Pavao independent director as founder Howard Berman exits board
Reuters · 3d ago
BUZZ-Janux Therapeutics up after nominating cancer therapy in Bristol Myers deal
Reuters · 4d ago
Janux nominates development candidate in Bristol Myers Squibb deal, triggers $35 million milestone
Reuters · 4d ago
ROVI closes acquisition of Bristol Myers Squibb pharmaceutical manufacturing plant in Phoenix, Arizona
Reuters · 4d ago
HBM FY25 profit jumps to US$ 92 million; revenue more than tripled to US$ 160 million
Reuters · 6d ago
Bristol Myers’ Camzyos cuts LVOT gradient in Phase 3 adolescent obstructive HCM trial
Reuters · 03/29 15:45
Takeda's psoriasis pill succeeds in late-stage studies
Reuters · 03/28 19:00
BRIEF-Bristol-Myers Squibb Says Open Label Outpatient Switch Study Demonstrates Symptom Stability During Transition From Oral Atypical Antipsychotics To Cobenfy
Reuters · 03/28 11:13
Bristol Myers says Phase 4 trial shows stable switch to schizophrenia drug Cobenfy
Reuters · 03/28 11:00
Bristol-Myers Squibb files Form 15 to deregister $2 convertible preferred stock; holders of record drop to zero
Reuters · 03/27 20:06
BRISTOL-MYERS SQUIBB CO SAYS CEO CHRISTOPHER S. BOERNER'S 2025 TOTAL COMPENSATION WAS $21.9 MLN - SEC FILING
Reuters · 03/25 20:20
Recursion names Vicki Goodman chief medical officer effective April 6, 2026; David Mauro exits after about three years
Reuters · 03/25 11:59
Bristol Myers Squibb-backed Viz HCM studies slated for presentation at ACC Scientific Session 2026
Reuters · 03/23 13:02
INSITRO: EXPANDING COLLABORATION WITH BRISTOL MYERS SQUIBB TO ADVANCE PORTFOLIO OF THERAPEUTIC PROGRAMS FOR AMYOTROPHIC LATERAL SCLEROSIS
Reuters · 03/23 12:05
Bristol Myers Squibb expands insitro ALS collaboration with two new targets and USD 10 million milestone payment
Reuters · 03/23 12:02
Bristol Myers Squibb reports Phase 3 SCOUT-HCM trial meets primary endpoint for Camzyos in adolescents with obstructive hypertrophic cardiomyopathy
Reuters · 03/23 10:59
BRISTOL MYERS SQUIBB REINFORCES LEADERSHIP IN OHCM WITH NEW CAMZYOS (MAVACAMTEN) DATA AT AMERICAN COLLEGE OF CARDIOLOGY ANNUAL SCIENTIFIC SESSION & EXPO 2026 (ACC.26)
Reuters · 03/23 10:59
Prothena partners present prasinezumab and BMS-986446 clinical study updates at AD/PD 2026
Reuters · 03/21 20:05
More
Webull provides a variety of real-time BMY-RT stock news. You can receive the latest news about Bristol-Myers through multiple platforms. This information may help you make smarter investment decisions.
About BMY-RT
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company's pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. Its products include Empliciti, Opdivo, Sprycel, Yervoy, Eliquis, Orencia, Baraclude, Hepatitis C Franchise, Reyataz Franchise and Sustiva Franchise. It offers products for a range of therapeutic classes, which include virology, including human immunodeficiency virus (HIV) infection; oncology; immunoscience, and cardiovascular. Its products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession across the world. Its subsidiaries are Celgene Corp and MyoKardia, Inc.